Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction)

Linde, Cecilia; Mealing, Stuart; Hawkins, Neil; Eaton, James; Brown, Breanna; Daubert, J.-C.

doi:10.1093/eurheartj/ehq408

Cited by 63 publications

(46 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The process is predicated on the use of mathematical models to identify trends in the clinical trial data and to project these trends forwards. Numerous examples of this process exist within the area of cardiology (see, for example, Linde et al 42 , Watt et al 40 , Gada et al 43 , Briggs et al 44 , Henriksson et al 45 , and Sculpher et al 46 ).…”

Section: Discussionmentioning

confidence: 99%

EVEREST II high risk study based UK cost-effectiveness analysis of MitraClip® in patients with severe mitral regurgitation ineligible for conventional repair/replacement surgery

Mealing

Feldman

Eaton

et al. 2013

Journal of Medical Economics

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

EVEREST II high risk study based UK cost-effectiveness analysis of MitraClip® in patients with severe mitral regurgitation ineligible for conventional repair/replacement surgery

Mealing

Feldman

Eaton

et al. 2013

Journal of Medical Economics

View full text Add to dashboard Cite

show abstract

“…Whether these adverse events were associated with rehospitalizations were unspecified. Adverse events related to device implantation should also be taken into consideration when judging the benefit and cost effectiveness of CRT (31). Study limitations.…”

Section: Discussionmentioning

confidence: 99%

Cardiac Resynchronization Therapy in Patients With Minimal Heart Failure

Adabag

Roukoz

Anand

et al. 2011

Journal of the American College of Cardiology

View full text Add to dashboard Cite

show abstract

“…[16][17][18] The reduction in hospitalizations and hospitalization days with CRT therapy observed in RAFT would be anticipated to result in substantial healthcare savings, but the magnitude of this benefit awaits the completion of a detailed cost-effectiveness analysis. [16][17][18] Given that hospital stay may vary dramatically by geographic region, we examined the duration of hospital stay for HF by geographic region: Australia, Canada, Europe, and Turkey. 19 The average length of stay was similar between regions.…”

Section: Crt and Hospitalizations For Hfmentioning

confidence: 99%

Impact of Cardiac Resynchronization Therapy on Hospitalizations in the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial

Gillis

Kerr

Philippon³

et al. 2014

Circulation

View full text Add to dashboard Cite

4-8 The Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) reported that patients with mild to moderate HF and depressed left ventricular systolic function in association with an intraventricular conduction delay randomized to an implantable cardioverter-defibrillator (ICD) plus CRT experienced improved survival and were significantly less likely to be hospitalized for HF compared with the group randomized to ICD therapy alone. 8 This prespecified study within RAFT presents a detailed analysis of the causes of hospitalization, hospitalization rates, and hospitalization lengths of stay in the RAFT cohort. Clinical Perspective on p 2030 MethodsThe study design 9 and results of RAFT 8 have previously been published. Patients were enrolled at 24 centers in Canada, 8 centers inBackground-This study reports the impact of cardiac resynchronization therapy (CRT) on hospitalizations in patients randomized to implantable cardioverter-defibrillator (ICD) or ICD-CRT in the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT). Methods and Results-Hospitalization rates and lengths of hospital stay were compared between the 2 groups. At the 18-month follow-up, the numbers of patients hospitalized for any cause were similar in the ICD (n=351, 38.8%) and ICD-CRT (n=331, 30.0%) groups. The number of patients hospitalized for heart failure was significantly lower in the ICD-CRT (n=101, 11.3%) compared with the ICD (n=141, 15.6%; P=0.003) group. The number of patients hospitalized for a device-related indication was similar in the ICD-CRT group (n=147, 16.4%) and ICD group (n=126, 13.9%; P=0.148). The total number of hospitalizations for any cause (n=1448 versus n=1553; P=0.042), any cardiovascular cause (n=667 versus n=790; P=0.017), and any heart failure cause (n=385 versus n=505; P<0.0001) was significantly lower in ICD-CRT group compared with the ICD group, whereas the number of hospitalizations for device-related causes was significantly higher in the ICD-CRT group compared with the ICD group (246 versus 159; P<0.001). Although the reduction in hospitalizations for heart failure in the CRT-ICD group was offset by an increased number of hospitalizations for device-related indications, the length of hospital stay for any cause was significantly shorter in the ICD-CRT group (8.83±13.30 days) compared with the ICD group (9.59±14.40 days; P=0.005). Conclusion-ICD-CRT therapy significantly reduces hospitalizations and total days in hospital in patients with New York Heart Association class II/III heart failure compared with ICD therapy despite increased admissions for device-related indications. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00251251.

show abstract

Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction)

Abstract: Cardiac resynchronization therapy is a cost-effective intervention for patients with mildly symptomatic HF and for asymptomatic patients with left ventricular dysfunction and previous HF symptoms.

Cited by 63 publications

References 28 publications

EVEREST II high risk study based UK cost-effectiveness analysis of MitraClip® in patients with severe mitral regurgitation ineligible for conventional repair/replacement surgery

EVEREST II high risk study based UK cost-effectiveness analysis of MitraClip® in patients with severe mitral regurgitation ineligible for conventional repair/replacement surgery

Cardiac Resynchronization Therapy in Patients With Minimal Heart Failure

Impact of Cardiac Resynchronization Therapy on Hospitalizations in the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial

Contact Info

Product

Resources

About